Medications and Supplements to Pause Before Treatment

The pre-procedure medication pause is the quiet, unglamorous chapter of any regenerative cell consultation in Seoul — and it is, in our reading, the chapter that separates the careful clinics from the merely competent ones. One arrives at the consultation with a half-remembered mental list — the daily aspirin, perhaps a fish-oil capsule, the 涼茶 a relative pressed into one's hand last month — and the operator at the better rooms will, without any visible impatience, walk through every entry. 講真嘅, the brief on what to pause is rarely flattering to the patient's record-keeping. The windows differ by drug class, by dose, by indication; the supplements complicate things further; and the herbal preparations — particularly those one has carried over from a Hong Kong, Taipei, or Shanghai chemist — are the category most often overlooked.

Why the pause matters — bleeding risk and cell-niche logic

The pre-procedure medication pause exists for two distinct reasons — and the distinction is rarely made plainly in the marketing literature, though it ought to be. The first is the conventional surgical-bleeding rationale: regenerative cell work in Seoul almost always involves a small-volume liposuction harvest under tumescent local anaesthesia, and any agent that prolongs bleeding time at the harvest site complicates the closed-system collection, the post-procedure haemostasis, and the bruise picture the patient carries home. The second rationale is more particular to cell work, and is, in our reading, the chapter the consumer-facing copy tends to skip. The injected cell suspension — whether stromal vascular fraction, cultured ADSC, or platelet-rich plasma adjunct — performs its proposed paracrine work in a tissue niche, and the niche is itself modulated by what the patient is taking. Anti-inflammatory medications, in particular, dampen the local cytokine signalling that the cell preparation is meant to recruit; the conservative reading is that a niche flooded with NSAID-derived prostaglandin suppression is a niche less responsive to the signalling the cells are designed to provide. Patients report — and the laboratory work, in some indications, supports — that procedural outcomes are more reliable when the niche is not pharmacologically quietened in the days before injection. The hedging here is genuine. Studies suggest the niche-modulation effect is dose-dependent and indication-dependent in ways the field has not finished characterising; what is not in doubt is that the more careful Korean operators treat the pause window as clinically meaningful rather than a procedural courtesy. One arrives, hands over the list, and is told — with reasons — what to pause and for how long. The room that hands back a generic printed pause sheet without reading the list one has prepared is the room one declines, gently, in favour of another consultation.

• Bleeding-rationale pauses: anticoagulants, antiplatelet agents, NSAIDs at higher doses
• Niche-rationale pauses: chronic anti-inflammatory regimens, immunomodulators, certain steroid courses
• Interaction-rationale pauses: agents that interact with the local anaesthetic or sedation protocol

Anticoagulants and antiplatelet agents — the longest pause windows

Anticoagulant and antiplatelet agents carry the longest, most carefully managed pause windows of any pre-procedure category — and the windows differ markedly by mechanism rather than by brand. Aspirin, taken at the daily cardioprotective dose of 75 to 100 milligrams, is conventionally paused for seven days before a regenerative cell harvest in Seoul; the irreversible inhibition of platelet cyclooxygenase that aspirin produces lasts the full lifespan of the affected platelet population, and the seven-day window allows the marrow to refresh the platelet pool. Clopidogrel and other thienopyridines carry a similar seven-day pause, for the same mechanistic reason. Direct oral anticoagulants — the apixaban, rivaroxaban, edoxaban, and dabigatran class — are paused on a shorter, dose- and renal-function-adjusted window, typically 48 to 72 hours, and the responsible clinic will request a recent estimated glomerular filtration rate before finalising the schedule. Warfarin, where it is still in use, is paused over a longer five-day window with INR re-checked at the consultation. The picture is more nuanced than a generic pause sheet suggests. A patient on dual antiplatelet therapy following a recent coronary stent placement is, in most Korean practices, deferred from elective regenerative work entirely until the dual-therapy window is complete; the bleeding-risk arithmetic does not favour the elective category. A patient on single-agent aspirin for primary prevention sits in a different conversation; in some cases, with cardiology sign-off, the pause is straightforward, and in others — particularly where the indication for aspirin is ambiguous — the consultation may surface the question of whether the agent is still indicated at all. The conversation, in the better rooms, is multidisciplinary by default. The American College of Cardiology's published guidance on perioperative antithrombotic management, available through the [American Heart Association journals portal](https://www.ahajournals.org/), is a useful reference for the framework; the local Korean practice tends to align with the conservative end of the international consensus. The pause window is rarely shortened to suit a travel itinerary. The room that offers to do so is, in our reading, the wrong room.

NSAIDs, paracetamol, and the over-the-counter category

The over-the-counter analgesic category is the one patients are most likely to under-disclose — and, in the niche-rationale framework above, the one that warrants the most attention. Non-steroidal anti-inflammatory drugs — the ibuprofen, naproxen, diclofenac, and celecoxib group — are conventionally paused for three to seven days before a regenerative cell procedure, depending on dose and half-life. The three-day window is appropriate for occasional ibuprofen at standard over-the-counter dosing; the longer seven-day window applies to higher-dose chronic users, particularly those on long-acting agents such as naproxen or piroxicam. The mechanistic concern is dual: NSAIDs modestly impair platelet function (the bleeding rationale) and, more relevantly for cell work, suppress local prostaglandin signalling at the injection site for several days after the last dose (the niche rationale). Paracetamol — acetaminophen, for the American spelling — is the conventional bridge analgesic across the pause window, as it does not significantly impair platelet function or prostaglandin signalling at therapeutic doses. The standard guidance from the better Korean clinics is that paracetamol at up to three grams daily is acceptable in the days leading up to the procedure, with the usual hepatic-load caveats for patients on multiple paracetamol-containing combination products. The category that warrants particular attention is the cold-and-flu combination tablet, which often contains an NSAID component the patient has not noticed; in our reading, this is the most common source of accidental NSAID exposure across a stated pause window. One reads the label of the cold tablet that the local pharmacy in Causeway Bay or Tsim Sha Tsui hands across the counter, and one is surprised, sometimes, by what is in it. The honest editorial register is to bring the actual packaging to the consultation. The clinic will read it. Aspirin in over-the-counter combination products — the analgesic-plus-caffeine class, occasionally found in headache-targeted formulations — sits in the same trap; the active ingredient list on the back of the box is the document that matters, not the brand name on the front. One does not assume.

• Pause 3-7 days: ibuprofen, naproxen, diclofenac, celecoxib, mefenamic acid
• Pause 3 days minimum at OTC dose; 7 days for chronic or higher-dose use
• Acceptable across the pause window: paracetamol up to 3g daily (hepatic-load caveats)
• Read the label: cold-and-flu combinations frequently contain hidden NSAIDs or aspirin

Herbal preparations — the category most often overlooked

The herbal preparation category is, in our editorial view, the most consistently under-disclosed in the pre-procedure consultation — and the category in which the bleeding-risk literature is most fragmented. The conventional pause list, drawn from the perioperative anaesthetic literature, includes the seven preparations most reliably associated with platelet inhibition or anticoagulant interaction: ginkgo biloba, garlic at supplemental concentrations, ginger at supplemental concentrations, ginseng (both Asian and American), feverfew, kava, and St John's wort. The pause window for each is conventionally seven to fourteen days, with the longer end of the range applied to chronic users. The list does not exhaust the relevant entries — and this is where the consultation conversation becomes culturally specific. A Hong Kong, Shanghai, or Taipei patient often arrives with a longer roster of preparations: the daily 涼茶, the chrysanthemum-based teas, the wolfberry tinctures, the licorice-containing herbal blends one's grandmother insists upon, the dong quai (當歸) preparations one might be using for menstrual regulation. Several of these — dong quai in particular, and licorice at higher doses — carry credible interaction concerns with the bleeding-risk and steroid-axis frameworks the procedure operates within. The conservative position is to pause anything one is taking by mouth for medicinal effect, regardless of whether it is dispensed in a Western pharmacy or a Tsim Sha Tsui herbalist's shop, for at least seven days before the procedure. The Memorial Sloan Kettering [About Herbs database](https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs) is a useful, hedged English-language reference for individual entries; one consults it without expecting it to settle every question. The conversation, in the better Korean rooms, is conducted with the actual containers in front of the patient. One unloads the supplement pouch onto the desk; the operator photographs the labels; the pause windows are written longhand on the consultation card. It is the most undramatic part of the visit. It is also the part that has, in our reading, prevented more bruise pictures and seroma incidents than any other component of the pre-procedure brief.

Common supplements — fish oil, vitamin E, and the wellness shelf

The wellness-supplement category is the one patients are most likely to consider trivial — and the one in which the platelet-modulation literature is, in fact, well established for several entries. Fish oil at supplemental concentrations (typically one to three grams of combined EPA and DHA daily) is conventionally paused for seven days before a regenerative cell harvest; the omega-3 fatty acids modestly impair platelet aggregation, and chronic high-dose users may carry the effect across a longer window. Vitamin E at supplemental concentrations above 400 international units daily is paused on a similar seven-day window for the same mechanistic reason. Garlic, ginger, and turmeric, when taken as concentrated supplements rather than as culinary ingredients, fall into the same category — culinary doses are not the concern, but the standardised extract capsules are. The wellness-shelf categories that do not require a pre-procedure pause, in most Korean practices, include single-ingredient B-vitamin supplements, vitamin D at routine replacement doses, calcium and magnesium preparations at standard formulations, probiotics, and most amino acid powders. The collagen peptide category — popular in the K-beauty wellness register — does not carry a pause requirement, though some clinics will ask the patient to discontinue any preparation containing added botanical extracts (the chrysanthemum, the elderflower, the assorted floribunda) that often appear in the more expensive marine-collagen formulations. One reads the back of the canister. One brings the canister, where uncertainty remains. The cannabidiol category — increasingly common in the Hong Kong and Singaporean wellness scene — sits in an unsettled regulatory and pharmacological space; the conservative position is to pause CBD products of any concentration for seven days before the procedure, on the strength of the cytochrome P450 interaction profile rather than any direct platelet effect. The clinic that asks about CBD without prompting is, in our reading, doing the careful version of the work.

Pause-window comparison table — at a glance

Below — categorically, not as a ranking, and on the understanding that the individual consultation refines the windows for each patient — is the pause-window framework the more careful Korean clinics tend to operate within. The table is descriptive rather than prescriptive; the consultation determines the actual windows, with adjustments for dose, indication, and concurrent medical conditions.

What to bring to the consultation — and how to make the list

The medication-disclosure conversation is the conversation the better Korean clinics conduct most thoroughly — and the one for which the patient can prepare meaningfully in the two weeks before travel. The honest editorial recommendation is straightforward, and it is the recommendation we offer to every reader: bring the actual containers, in the actual quantities one is taking, in a single transparent pouch or zippered cosmetic bag, to the consultation desk. The photographed-on-a-phone version of the list is acceptable for prescription medications where the original packaging has been transferred to a weekly pill organiser; it is not acceptable, in our experience, for supplements and herbal preparations, where the dose, the brand, and the supporting ingredient list are all material to the pause-window decision. A second item the better consultations request is a brief written history: which medications were started in the past twelve months, which were discontinued in the same window, and which were prescribed by a clinician versus selected from the wellness shelf. The distinction matters. A medication prescribed by a cardiologist for atrial fibrillation carries a different pause-window conversation than a fish-oil capsule selected at a Causeway Bay pharmacy; the prescriber's voice belongs in the former conversation, and not in the latter. The clinic will, in most cases, ask for the cardiologist's contact details directly. A third, smaller note: the consultation is the appropriate moment to surface medications one might be embarrassed to disclose — the recreational-use admissions, the over-the-counter sleep aids, the appetite suppressants ordered through a non-prescription channel. The consultation is, in the rooms one trusts, a confidential conversation. The Hong Kong-shopped sleeping tablet is not a moral failure; it is a clinical fact the operator needs in order to plan the harvest safely. One discloses without varnish. The room that handles the disclosure with the same matter-of-factness it would apply to a prescription is the room one returns to. The Hong Kong Hospital Authority's [Drug Office reference portal](https://www.drugoffice.gov.hk/) is a useful pre-departure resource for patients consolidating their list before travel; the Korean consultation refines what the patient brings rather than constructing the list from scratch.

Resuming medications post-procedure — the quieter half of the conversation

The post-procedure resumption schedule is the half of the medication conversation that receives less editorial attention than it deserves — and the half on which, in our reading, the better Korean clinics differentiate themselves most clearly. Cardioprotective aspirin, where it has been paused, is conventionally resumed 48 to 72 hours after the procedure, on confirmation that the harvest site has stabilised and there is no oozing or expanding bruise; the resumption is timed under cardiology guidance for patients with a stent or recent coronary event. Direct oral anticoagulants are resumed on a similar 48 to 72 hour window, with the same hand-off to the cardiologist. NSAIDs are, in most Korean practices, deliberately held back for a longer two- to four-week window after the cell injection — and the rationale here is the niche-modulation logic discussed above, rather than bleeding risk. The proposed paracrine work the cells are doing in the injection-site niche is, on the prevailing model, more reliably supported when local prostaglandin signalling is allowed to run uninterrupted in the early weeks. Patients report — and the operators recommend — paracetamol as the analgesic of choice across the post-procedure window, with NSAIDs reintroduced cautiously after the four-week mark if needed for an unrelated indication. Herbal preparations and supplements are reintroduced on a more individualised schedule. The conservative editorial position — and the position the more thoughtful Korean clinics tend to take — is to wait two weeks before reintroducing any preparation with a credible bleeding-modulation profile, and to reintroduce one entry at a time over the subsequent month, so that any unexpected response can be attributed to a specific preparation rather than the entire pouch. The consultation card one carries home, in the rooms one trusts, has all of this written longhand. It is, in our reading, the document worth keeping.

Frequently asked questions

I take a daily low-dose aspirin for cardiovascular prevention. Will I need to pause it for the procedure?

Almost certainly, yes — the conventional pause window for cardioprotective aspirin before a regenerative cell harvest is seven days, on the strength of aspirin's irreversible platelet inhibition. The pause is coordinated with one's cardiologist or general practitioner, particularly for patients with a recent coronary event or stent placement. In some cases, a patient on aspirin for primary prevention only may, after a multidisciplinary review, find that the medication is no longer formally indicated; the consultation is the moment that question can surface. Resumption is typically 48 to 72 hours after the procedure, under the same cardiology guidance.

I take fish oil and vitamin E daily. Are these supplements I really need to pause?

Yes — both are paused for seven days before the procedure in the conventional pre-operative literature, on the strength of their modest platelet-aggregation effects at supplemental concentrations. Fish oil at one to three grams of combined EPA and DHA daily, and vitamin E above 400 international units daily, both warrant the pause. Resumption is typically two weeks post-procedure, in line with the broader supplement reintroduction schedule. The hedging is genuine — the clinical effect is modest at standard supplement doses — but the conservative editorial position is to honour the pause rather than negotiate it.

What about traditional Chinese herbal preparations? My grandmother gives me a daily tea.

The herbal preparation category warrants particular attention, and the conservative position is to pause anything taken by mouth for medicinal effect — including teas, tinctures, and powdered preparations — for at least seven days before the procedure, with a fourteen-day window for chronic users of preparations with credible bleeding-risk profiles (ginkgo, ginseng, dong quai, garlic supplements at concentrated doses). Bring the actual containers or a photograph of the ingredient list to the consultation. The clinic will work through them entry by entry; this is the unglamorous chapter of the visit, and it is also the chapter that prevents most pre-procedure complications.

Can I take paracetamol or acetaminophen during the pause window if I have a headache?

Yes — paracetamol at up to three grams daily is the conventional bridge analgesic across the pause window, as it does not significantly impair platelet function or prostaglandin signalling at therapeutic doses. The usual hepatic-load caveats apply for patients on combination products that contain paracetamol alongside other analgesics, and one reads the label of any cold-and-flu tablet to confirm the active ingredient list. Cold-and-flu combinations frequently contain a hidden NSAID component, which the pause window does not permit.

How long after the procedure can I resume my regular medications and supplements?

The schedule depends on the agent. Cardioprotective aspirin and direct oral anticoagulants are typically resumed 48 to 72 hours post-procedure, under cardiology guidance, on confirmation that the harvest site has stabilised. NSAIDs are held for a longer two- to four-week window, on the niche-modulation rationale rather than bleeding risk. Herbal preparations and wellness supplements are reintroduced one at a time over the month following the procedure, beginning at the two-week mark, so that any unexpected response can be attributed to a specific entry. Paracetamol is acceptable throughout for analgesia.

What if I forgot to pause a medication and only realised the morning of the procedure?

Tell the clinic before the harvest begins — promptly, without varnish, and ideally before one is in the procedure room. Depending on the medication and the dose, the operator may proceed with a modified plan, defer the procedure to a rescheduled date, or — for higher-risk agents such as the direct oral anticoagulants taken within twenty-four hours of the procedure — defer outright. The room one trusts handles this disclosure with the same matter-of-factness it applies to any other clinical detail. There is no version of this conversation in which concealment improves the outcome.

Are CBD products something I need to disclose? They are over-the-counter where I live.

Yes — cannabidiol products warrant disclosure regardless of regulatory status in the patient's home jurisdiction. The conservative editorial position is to pause CBD products of any concentration for seven days before the procedure, on the strength of the cytochrome P450 interaction profile (CBD modulates the hepatic enzymes that metabolise the local anaesthetic and several common bridge analgesics) rather than any direct platelet effect. The clinic that asks about CBD without prompting is doing the careful version of the work.